The androgen receptor: Genetic considerations in the development and treatment of prostate cancer

Kelly J. Cude, Shannon C. Dixon, Yi Guo, Jordan Lisella, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


The action of androgens in the development and growth of prostate carcinomas is well documented. The androgen receptor (AR) facilitates androgen-induced regulation of genes involved in cellular proliferation and differentiation. Since the early 1940s androgen ablation has been the cornerstone of treatment for metastatic prostate cancer. Although initially highly effective, hormonal therapy is not curative, and resistant disease will ultimately prevail. Mutations that alter AR conformation, function, and regulation may provide a selective growth advantage for subpopulations of cells within the tumor that are then able to proliferate in an androgen- deprived environment. Clinically, these mutations are important because they may lead to the growth of androgen-independent tumors and progression to a refractory state. Further characterization of AR mutations will lead to a more thorough understanding of their role in the development of prostate carcinomas. This information, in addition to discovering which genes are regulated by the AR, can aid in the future development of more effective pharmacotherapy for prostate cancer.

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalJournal of Molecular Medicine
Issue number5
StatePublished - 1999
Externally publishedYes


  • Androgen receptor
  • Hormone ablation
  • Prostate cancer


Dive into the research topics of 'The androgen receptor: Genetic considerations in the development and treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this